The development of new drugs is a critical aspect of healthcare, yet over 50% of new drug developments fail due to inadequate therapeutic efficacy in clinical trials. This is particularly true for novel compounds of large molecules and biologics that are human-specifically targeted, despite advanced research data obtained from small animal models. To increase the success rate of new drug development, Prisys offers innovative nonhuman primate (NHP) pharmacology models and related technologies to global pharmaceutical industries for more meaningful studies that have direct relevance to clinical applications.

Prisys' NHP models encompass a broad range of disease areas, including immunology, inflammation, hematology, nephrology, hepatology, pulmonology, and gynecology, among others. Moreover, Prisys continues to expand its NHP models and works in partnership with sponsors to co-develop customized models.

Please contact us for the most up-to-date and comprehensive list of Prisys' NHP disease models. Our NHP models and cutting-edge technology provide an excellent opportunity to improve the success of new drug development by increasing the relevance and accuracy of preclinical studies.

http://www.prisysbiotech.com/